异动解读 | Blueprint Medicines Corporation股价盘中大涨5.25%,可能与其生物制药业务前景看好有关

异动解读
Nov 06, 2024

2024年11月5日,Blueprint Medicines Corporation(BPMC)股价在盘中出现大涨,最高上涨5.25%,引发市场广泛关注。

作为一家专注于治疗罕见疾病的生物制药公司,BPMC正在开发多种潜在药物,如用于系统性肥大细胞增多症的AYVAKIT,治疗肥大细胞相关疾病的BLU-808,以及用于乳腺癌的BLU-956和BLU-222等。

分析人士认为,BPMC股价上涨或与投资者对公司药物管线和业务前景的乐观预期有关。该公司最新财报显示营收达1.28亿美元,虽然净利润为负,但市场可能更看重其在罕见病领域的创新潜力。机构投资者对BPMC也较为看好,约70%的机构给予买入评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10